In brief

  • The list of medicines that the health insurance house reimburses for patients treated under the national health programmes changes in 75 positions: 50 are amended, 20 are added and 5 are repealed, across 16 lists covering five programmes, from HIV/AIDS and tuberculosis to oncology, rare diseases and transplantation.
  • The reimbursement price is what the insurance house pays, not what the patient pays. The sum due at the counter sits in the last column of the list, the maximum contribution of the insured person, and the widest gap in the whole order appears at eltrombopag 50 mg, a medicine for chronic immune thrombocytopenic purpura: for Revolade the patient pays 4,676.00 lei for the pack of 28 tablets, while for the new Eltrombopag Dr. Reddy’s, the same substance in the same strength, the patient pays nothing.
  • The order was published on 8 October 2026, yet it provides that it applies „starting with the month of October 2026”, which means it claims effects for the seven days before publication as well. This is the third month in a row in which the list appears with the same wording.
Act: Order of the interim minister of health no. 1.728/2026 and of the president of the National Health Insurance House no. 1.769/2026
Published: Official Gazette of Romania, Part I, no. 847 of 8 October 2026, pages 5-14
In force from: 1 October 2026, the date claimed by Article II through the formula „starting with the month of October 2026”, even though publication took place on 8 October 2026

The list of commercial names and reimbursement prices of the medicines in the national health programmes changes in 75 positions. The joint order signed by the Ministry of Health, under no. 1.728 of 7 October 2026, and by the National Health Insurance House (CNAS), under no. 1.769 of 29 September 2026, rewrites Annex no. 2 to Order no. 1.605/875/2014, that is, the very table a pharmacy or a hospital opens when it dispenses a medicine under a programme. This is the third monthly update in a row, after the order of 7 September 2026, which touched 39 positions, and after the one of 11 August 2026, which touched 79. In three months the list has changed in 193 positions, roughly 64 a month.

The money behind these lists changed in turn, through the budget of the national public health programmes, cut in October 2026.

One thing needs clearing up before the figures, because the name of the column misleads. The „reimbursement price” is not the sum the patient takes out of pocket, but the sum the insurance house pays the pharmacy or the hospital for one therapeutic unit, that is, for a tablet, a capsule or a vial. What the patient pays appears separately, in the column for the maximum contribution of the insured person in community pharmacies, and it is the difference left between the price of that particular product and the share covered by the fund. For two packs of the same substance, in the same strength, the contribution can be several thousand lei or nothing at all, and nowhere does the order say so. Dialysis and the new hospitals in the CNAS programmes, with the per-session tariffs, are in the technical rules of the national curative programmes.

The changes fall into three categories. Fifty existing positions receive new content, twenty new positions enter the list, and five leave it: three from the national oncology programme, positions 379, 390 and 401, one from the diabetes mellitus programme, position 78, and one from the pulmonary hypertension sub-programme, position 28. The positions taken out appear only as sequence numbers, with no commercial name and no code, so a patient cannot find out from the order whether their own brand has gone. Sixteen lists are touched: the two lettered sections of the communicable diseases programme, HIV/AIDS and tuberculosis, oncology, diabetes mellitus, five rare disease sub-programmes and all seven transplantation sub-programmes.

The 28 points of the annex look like more things than they are. Of the 70 positions written out under letters, that is, the amendments and the additions, 24 concern a single medicine: voriconazole powder for solution for infusion 200 mg, in three commercial versions. The substance appears in eight different lists, from HIV/AIDS through to each of the seven transplantation sub-programmes, and in every one of them the two older products are amended and a new one is added. Three products written eight times make up almost a third of the annex. For five anti-tuberculosis medicines, isoniazid 100 mg and 300 mg, pyrazinamide, ethambutol and the rifampicin plus isoniazid combination, the same values are repeated twice, once under HIV/AIDS and once under tuberculosis. All told, the 70 rows cover 42 distinct products and 16 substances.

Six of the twenty new positions are medicines entering the list for the first time, four of them in oncology. The most expensive is Lunsumio, mosunetuzumab, an antibody used in lymphomas, at 34,991.09 lei for the 45 mg vial and 3,914.55 lei for the 5 mg vial. Alongside it come Xbryk, denosumab 120 mg, at 711.54 lei a vial, and Hydrea, hydroxycarbamide 500 mg, at 0.945 lei a capsule, that is, 94.50 lei for the pack of 100. Between the most expensive and the cheapest of the newly added oncology products the ratio is more than 37,000 to one. In idiopathic pulmonary fibrosis, Esbriet, pirfenidone, enters in both pack sizes.

The other 14 new positions are cheaper versions of medicines already on the list, and they explain why everything that changes, changes. In come a voriconazole from Accord, an azacitidine from Rompharm, an albumin-bound paclitaxel from Dr. Reddy’s, two strengths of eltrombopag from Dr. Reddy’s and a biosimilar eculizumab, Epysqli, from Samsung Bioepis. Each of them arrives with a reimbursement price exactly one sixth below the reference price of its group, and the other products in that group are recalculated accordingly.

What it changes in practice

The largest effect in money shows at eltrombopag, an oral treatment for chronic idiopathic immune thrombocytopenic purpura, a disease in which the body destroys its own platelets. The sub-programme now holds six products for each of the two strengths, and the patient’s contribution differs from one to the next with no connection at all to the dose received. At 50 mg, per pack of 28 film-coated tablets: 4,676.00 lei for Revolade, 3,656.18 lei for Tocieta, 3,597.98 lei for Eltrombopag Teva, 2,451.17 lei for Eltrombopag Accord, 1,617.69 lei for Eltrombopag Stada and nothing for the new Eltrombopag Dr. Reddy’s. At 25 mg, again per pack of 28: 2,333.86 lei for Revolade, 1,272.06 lei for the Teva version, 1,195.06 lei for Accord, 1,162.58 lei for Tocieta, 511.91 lei for Stada and nothing for Dr. Reddy’s. The patient does not choose; the prescription and the pharmacy’s stock choose.

The second large effect is the arrival of the first biosimilar eculizumab. In atypical haemolytic uraemic syndrome and in paroxysmal nocturnal haemoglobinuria, Soliris stands at a reimbursement price of 15,055.680000 lei for the 300 mg vial and at an insured person’s contribution of 945.036000 lei a vial. The new Epysqli, the same 300 mg, enters with a reimbursement price of 12,546.400000 lei and a contribution of nothing. For the fund the difference is 2,509.28 lei on every vial; for the patient, the sum due at the counter falls from 945.04 lei to zero, on every vial administered.

In oncology, azacitidine reaches seven positions, all at the same strength of 100 mg a vial. The patient’s contribution runs from 277.136000 lei a vial for the Zentiva version, 183.116000 lei for Betapharm, 161.876000 lei for the two Sandoz versions and 64.336000 and 64.386000 lei respectively for Accord and Stada, down to zero for the new Rompharm azacitidine. For albumin-bound paclitaxel the contribution is 2,021.450000 lei for the 100 mg vial of Naveruclif and 919.720000 lei for Bugvi, while for the new product from Dr. Reddy’s it is nothing. On a single vial, the gap between the first and the last version is more than twenty times the price of a whole 100-capsule pack of Hydrea.

At voriconazole, the substance that takes up almost a third of the order, the situation repeats itself identically across all eight lists. The Zentiva version comes with a contribution of 371.834000 lei for the 200 mg vial, the Fresenius Kabi version with 45.124000 lei, and the new Accord version with nothing. A transplant patient receiving intravenous voriconazole therefore pays 371.83 lei, 45.12 lei or nothing for every vial, depending on what is written on the box the pharmacy hands over.

Two effects are small in money and large in meaning. In the epidermolysis bullosa sub-programme, the disease that makes the skin come away at the slightest touch and is usually diagnosed in childhood, tetracycline 250 mg stays at a reimbursement price of 0.324048 lei a capsule and a contribution of 0.544136 lei a capsule. For the pack of 20 capsules the fund pays 6.48 lei and the family 10.88 lei, that is, 62.7% of the total price of an antibiotic more than sixty years old. In the tuberculosis programme, the large packs of 1,500 tablets keep a contribution: 44.05 lei for isoniazid 100 mg, 61.05 lei for the 300 mg one and 72.39 lei for ethambutol 400 mg, while pyrazinamide and the Sinerdol ISO combination are dispensed with no payment at all.

The third effect is one of information, not of money. The five repealed positions are named nowhere, neither in the order nor in its annex. A cancer patient, a person with diabetes or a patient with pulmonary hypertension has no way of learning from the Official Gazette of Romania (Monitorul Oficial) whether their medicine has left the list. The only route left is comparison with the consolidated version of the annex, which the National Health Insurance House makes available a few days later.

What has changed compared with the previous situation

The order does not print the old values, only the new content of each position, so the direction of the change cannot be read straight from the act. The mechanism can be reconstructed, however, and it explains why the points of the annex go in pairs. Annex no. 1 to the basic order provides that the reimbursement price of a medicine dispensed through open-access pharmacies is obtained by applying 120% to the lowest price in the group made up of the same substance, pharmaceutical form and strength, and that if a product’s own price is lower than the result of that calculation, its own price becomes the reimbursement price. In short: the cheapest product in the group sets the threshold, and the rest are reimbursed at 120% of it.

The arithmetic checks out to the last decimal in all five groups touched now. Accord’s voriconazole enters at 322.100000 lei a vial, and 322.100000 multiplied by 1.2 gives exactly 386.520000, the new value of the other two 200 mg voriconazoles. Rompharm’s azacitidine enters at 323.940000 lei a vial, and multiplied by 1.2 it gives exactly 388.728000, the new value of the six azacitidines already listed. Dr. Reddy’s paclitaxel enters at 640.000000 lei, and 640 times 1.2 gives exactly 768.000000, the new value of Naveruclif and of Bugvi. Dr. Reddy’s eltrombopag enters at 4.411428 lei for the 25 mg tablet and at 6.889642 lei for the 50 mg one, and multiplied by 1.2 they give exactly 5.293714 and 8.267570, the new values of the other five versions in each strength. Epysqli enters at 12,546.400000 lei a vial, and multiplied by 1.2 it gives exactly 15,055.680000, the new value of Soliris. The twenty-eight points are not independent lists: they are five relationships of cause and effect, plus a list of new products.

The same arithmetic also yields the order of magnitude of the saving. Every new product is reimbursed one sixth below the reference price of its group, that is 16.67% less: 64.42 lei on the voriconazole vial, 64.788 lei on the azacitidine one, 128.00 lei on the paclitaxel one, 2,509.28 lei on the eculizumab one, 24.70 lei on the pack of 25 mg eltrombopag and 38.58 lei on the 50 mg one. The total depends on how many packs are dispensed, and that the order does not say.

At the newly entered products, which have no group to be compared against, something else comes into view. Esbriet appears in two pack sizes, 252 tablets of 267 mg and 84 tablets of 801 mg, at 28.258214 and at 84.774642 lei a tablet. The dose ratio is three to one, the price per tablet is three to one as well, and the quantity of pirfenidone in the pack is the same in both, 67,284 mg, so the two packs cost the fund exactly the same: 7,121.07 lei each. At Lunsumio, the two strengths come in at 777.58 lei a milligram for the 45 mg vial and at 782.91 lei a milligram for the 5 mg one, a difference of 0.68%, so the small pack is not penalised there either.

Compared with the previous months, the scale has grown. The update of 11 August 2026 touched 79 positions, the one of 7 September 2026 touched 39, and this one touches 75. The basic order requires the list to be updated quarterly or whenever needed; in practice the rhythm has been monthly for at least three months.

The monthly rhythm held in November as well. Under Order of the Minister of Health no. 211/2026 and of the President of the National Health Insurance House no. 1.940/2026, published on 5 November 2026, the list of medicines reimbursed in the national programmes changes in another 33 positions, and a second 120 mg denosumab in two months enters oncology.

Advantages and disadvantages

What it improves

  • Five substances gain a version with a zero contribution: voriconazole, azacitidine, albumin-bound paclitaxel, eltrombopag in both strengths and eculizumab. For the patient who receives the new product, payment at the pharmacy disappears.
  • The new product is reimbursed one sixth below the rest of its group, so the fund pays less for every pack dispensed of it, beyond the patient’s pocket. At eculizumab, the difference is 2,509.28 lei on the 300 mg vial.
  • The first biosimilar eculizumab enters the list for a rare disease where until now there was a single product, so an alternative source of supply appears alongside the price alternative.
  • Oncology receives six entirely new positions, among them an antibody for lymphomas and a denosumab, and idiopathic pulmonary fibrosis receives both pirfenidone pack sizes at once, so the dose can be adjusted without one form missing from the list.
  • The new voriconazole is introduced simultaneously in all eight lists in which the substance appears, with the same figures, so no reimbursement differences arise between a patient with HIV and a transplant patient treated with the same antifungal.

What remains a problem

  • The date of application, „starting with the month of October 2026”, comes before the publication of 8 October 2026 and leaves seven days in which nobody knows which price applies.
  • The five repealed positions appear only as sequence numbers. Neither the patient nor the pharmacist learns from the order which medicines have left the list.
  • The contribution stays very different between brands of the same substance, and the choice does not belong to the patient. At eltrombopag 50 mg, the distance between the ends of the range is 4,676.00 lei for the pack of 28 tablets.
  • Nothing in the order signals that a zero-contribution version exists. The piece of information that actually changes the patient’s bill is the hardest to find in the whole act.
  • The order does not publish the previous values, so the act itself cannot tell the reader whether a position has gone up or down.
  • A third of the annex is taken up by writing out the same three voriconazole products eight times, because the list keeps one row for each programme. The size of the act says nothing about how much has in fact changed.
  • In the sub-programme for atypical haemolytic uraemic syndrome and paroxysmal nocturnal haemoglobinuria, the same product appears on two consecutive positions, with the same identification code and the same figures, and the new one is brought in the same way, on positions 8 and 9. The order does not say what distinguishes one from the other.

Practical advice

  1. Before the medicine is handed over, ask the pharmacist what the contribution is for the product written on your prescription. It is the only sum you pay, and it can differ by thousands of lei between brands of the same substance.
  2. If you take eltrombopag, whether Revolade or a generic, ask your treating doctor whether the version with a zero contribution can be prescribed for you. At 50 mg the difference is 4,676.00 lei for the pack of 28 tablets.
  3. The same holds for azacitidine, for albumin-bound paclitaxel, for intravenous voriconazole and for eculizumab. In each of these groups there is now, from 8 October 2026, at least one product with no payment at the community pharmacy.
  4. Keep the receipt and the prescription for medicines dispensed between 1 and 7 October 2026. The order claims effects from the start of the month even though it appeared on 8 October, so if a different contribution was calculated for you, you have something to take to the health insurance house.
  5. If you are in the oncology programme, in the diabetes mellitus programme or in the pulmonary hypertension sub-programme, check the consolidated version of Annex no. 2 on the website of the National Health Insurance House. Five positions were taken out without being named.
  6. Do not change the brand of your medicine on your own. Substitution is done by the doctor or by the pharmacist, within the limits of the prescription, and a pack with a different commercial name may also carry a different dose per unit.
  7. If the pharmacy asks you for more than the value in the list, ask for the explanation in writing. The column is called maximum contribution, so it cannot be exceeded.

Frequently asked questions

Is the reimbursement price what I pay at the pharmacy?
No. The reimbursement price is the sum the insurance house pays the pharmacy or the hospital for one therapeutic unit, that is, for a tablet, a capsule or a vial. What you pay appears in the column for the maximum contribution of the insured person, in the same list, and it can be zero.
From when do the new prices apply?
The order was published on 8 October 2026 and provides that it applies „starting with the month of October 2026”. The two statements do not overlap, because an order of this kind enters into force on the date of publication or on a later date, never earlier. For 1 to 7 October 2026 the situation remains unclear.
What has changed in concrete terms for a patient taking eltrombopag?
A sixth version has appeared for each of the two strengths, Eltrombopag Dr. Reddy’s 25 mg and 50 mg, with a zero contribution. At the same time, the reimbursement price of the other five versions was set at 120% of the price of the new version. The contribution for those other versions still runs between 511.91 and 4,676.00 lei for the pack of 28 tablets, depending on brand and strength.
Which medicines have been taken off the list?
The order repeals positions 379, 390 and 401 in the national oncology programme, position 78 in the diabetes mellitus programme and position 28 in the pulmonary hypertension sub-programme, but it does not name them. The names can only be established by comparing with the previous consolidated version of Annex no. 2.
If my medicine has been taken off, am I left without treatment?
Not necessarily. A position leaving the list means that this commercial name is no longer reimbursed under the programme, but the substance usually remains available under other commercial names in the same group. Talk to the doctor who follows your case.
Why do I pay a contribution if I am in a national health programme?
Because in community pharmacies the fund reimburses a reference value calculated from the cheapest product in the group, and the difference up to the price of the product actually received stays with the insured person. If the product is the cheapest one in the group, the contribution is zero.
Which new medicines enter oncology?
Six positions: Lunsumio, mosunetuzumab, in vials of 45 mg at 34,991.09 lei and of 5 mg at 3,914.55 lei; Xbryk, denosumab 120 mg, at 711.54 lei a vial; Hydrea, hydroxycarbamide 500 mg, at 94.50 lei for the pack of 100 capsules; plus an azacitidine and an albumin-bound paclitaxel, cheaper versions of substances already listed. All of them enter with a zero contribution.
Why does voriconazole appear so many times?
Because Annex no. 2 keeps a separate row for every programme and sub-programme in which a substance is reimbursed, and voriconazole appears in eight of them: in HIV/AIDS and in all seven transplantation sub-programmes. The same three products are therefore written out eight times, with the same figures, which gives 24 of the 70 positions written out in the annex.

Errors and inconsistencies in the published text

  • Article II, the date from which the order applies. The text provides that the order is published in the Official Gazette of Romania, Part I, and enters into force „începând cu luna octombrie 2026”, that is, starting with the month of October, while publication took place on 8 October 2026. Article 12(3) of Law no. 24/2000 on legislative drafting rules provides that the normative acts listed in Article 11(1), with the exception of laws and ordinances, enter into force on the date of publication in the Official Gazette of Romania, Part I, „if no later date is provided for in their content”, and Article 11(1) expressly includes the orders issued by the heads of central specialised public administration bodies. The month of October 2026 is not a date later than publication, it is an interval that begins seven days before it, and Article 15(2) of the Constitution provides that the law disposes only for the future. A pharmacist reading the act in good faith can reach two different conclusions for prescriptions dispensed between 1 and 7 October 2026: either the new prices apply, or the old ones do. The difference is money and the patient carries it, 166.999857 lei on the 50 mg Revolade tablet, for instance, that is 4,676.00 lei on the pack of 28. The same wording appears for the third month in a row, after the order published on 11 August 2026 for „luna august 2026” and the one published on 7 September 2026 for „luna septembrie 2026”, so it has become a pattern rather than an isolated slip.

Editorial analysis

The order does one good thing and does it well: it brings five cheaper products into the list and, through the mechanism in Annex no. 1 to the basic act, sets the reimbursement price of the whole group at exactly 120% of that of the new product. The arithmetic closes to the sixth decimal in all five groups, which shows that the values come out of a formula and not out of case-by-case negotiation. The most important of the new products is Epysqli, the first biosimilar eculizumab on the list, which cuts reimbursement by 2,509.28 lei on every 300 mg vial and takes a contribution of 945.036000 lei a vial down to zero, in a rare disease where treatment is given for years.

The calculation is not the weak part. The weakness lies in the fact that nothing in the act tells the patient what has changed for them. Somebody taking Revolade 50 mg learns from the order that the reimbursement price of their medicine has fallen, but does not learn that a few positions further down exactly the same substance has entered, in the same strength and in the same pack of 28 tablets, with a zero contribution. The difference between the two rows is 4,676.00 lei a pack, more than a net minimum wage. The information that would actually change the patient’s bill is there in the act, but only for someone who knows to compare point 10 with point 11.

The second observation comes out of the chronology of the signatures. The president of the National Health Insurance House signed on 29 September 2026, one day before the start of the month the list is written for, so at the insurance house the act was ready in time. The interim minister of health signed on 7 October 2026, eight days later, and publication followed on 8 October. The seven days of application claimed before publication therefore come from the interval between the two signatures, not from a list that was not ready. The same distance appeared in the previous months, and the formula „starting with the month” has been repeated three times in a row, as though the date of application were a matter of internal administrative convention.

The third observation concerns the shape of the list. Of the 70 positions written out under letters, 24 are three voriconazole products rewritten eight times, and another ten are five anti-tuberculosis medicines written twice. That is 34 rows for 8 products, because Annex no. 2 keeps one row for every programme in which a substance is reimbursed. The result is a ten-page act of which a third brings no new information compared with the first appearance of the same row, while the checking effort demanded of pharmacies and hospitals grows in proportion. In the same rare disease sub-programme, the same product is listed twice in succession, on positions 3 and 4 for Soliris and on positions 8 and 9 for Epysqli, with the same identification code and the same figures, without the order saying what sets them apart.

What should be changed

  • A fixed date of application, instead of a month. Replacing the formula „starting with the month of October 2026” with a calendar date later than publication would close the ambiguity for the first days of the month and take reimbursements out of the interpretable zone. As things stand, for prescriptions dispensed between 1 and 7 October 2026 the pharmacy and the insurance house can arrive at two different sums for the same medicine.
  • Marking the groups in which a zero-contribution version exists. A sign in the list, on every position in the group, would tell the prescribing doctor and the pharmacist that the patient has a choice. Without it, the 4,676.00 lei difference on a pack of eltrombopag depends on how well somebody knows the list.
  • The names of the medicines at the repealed positions. The five positions taken out should appear with their commercial name and identification code, so that the patient learns from the order, not from a comparison of lists, whether their product has left reimbursement.
  • A column with the previous value, at the amended positions. The old price written next to the new one would show the direction of the change without forcing anyone to reconstruct the consolidated list. As it stands, the 50 amended positions do not say whether they went up or down.
  • A single appearance for each product, with the programmes set out in a column. If the row had a column listing the programmes in which the substance is reimbursed, the 24 voriconazole positions would come down to three and the ten anti-tuberculosis ones to five. The annex would shrink by about a third, and the risk of amending one row and forgetting its copy in another sub-programme would disappear.
  • A shorter interval between the two signatures. Eight days between the signature of the National Health Insurance House, on 29 September 2026, and that of the Ministry of Health, on 7 October 2026, means a week of the month the list applies to going by before the list exists in public. Signing in the same week would make the formula „starting with the month” unnecessary, because publication would catch the start of the month.
  • Clarification of the double positions in sub-programme P6.30. Either the act explains what distinguishes position 3 from position 4 for Soliris and position 8 from position 9 for Epysqli, or the two are merged. Two identical rows for the same product, in the same list, are an invitation to double reporting.

Original text of the legal act

The text below is reproduced in Romanian, the official form of publication.

The full text, as published in the Official Gazette of Romania

Official Gazette of Romania no. 847 of 8 October 2026, pages 5-14 16 pages PDF, 110 KB the act starts on page 5

Open the official PDFDownload the PDF

The viewer is not shown on small screens. Use the buttons above to open or download the file.

This article is for informational purposes only and does not constitute legal advice. For specific situations, consult a licensed attorney or tax advisor.